Dewpoint Therapeutics
John earned a B.S. in Biochemistry and Microbiology from the University of Massachusetts Amherst, and a Ph.D. in Biology from MIT. During his graduate work with Rick Young, John studied multiple aspects of transcriptional regulation, including genome structure and phase separation. John is thrilled at the opportunity to help translate these basic sciences to treatments for the most pressing diseases and to learn the ins and outs of a new biotech company.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.